All News

A retrospective study of 76 patients at a Spanish allergy clinic found occupational exposure suspected in more than half of chronic hand eczema cases, with patch testing tying most sensitizations to preservatives, nickel, and rubber accelerants.

Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step therapy falls short.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.

A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease and younger adults.

A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

New smartwatch data show women's nighttime awakenings jump sharply at midlife—far more than men's—hinting at a menopause-linked sleep shift.

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

Moderna’s mRNA flu vaccine receives FDA approval after phase 3 data showed improved efficacy compared with standard flu vaccines.

CANN says the revised pilot reflects stakeholder input and aims to address accountability challenges in the more than $100 billion 340B program.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

Lilly opens early access to retatrutide for some patients before FDA approval, following scrutiny over a single earlier compassionate-use case.

The former deputy surgeon general takes over an agency that has lacked permanent leadership since Susan Monarez, PhD, was ousted.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

The accreditation body targets sourcing, testing, and marketing practices, as the FDA advisory panel recommends expanding access to compounded peptides.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models, citing Taiwan's TALENT cohort as evidence broader eligibility finds cancer earlier.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Boston heart failure specialists discussed diagnostic gaps, cost barriers to newer therapies, and scalable care models for HFpEF and HFmrEF.